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Abstract 
Background: Combination therapy with artesunate plus sulfadoxine-pyrimethamine (SP) was adopted as recom-
mended treatment for Plasmodium falciparum infection in Afghanistan in 2003.
Methods: A series of prospective clinical studies examining the efficacy of artesunate plus sulfadoxine-pyrimeth-
amine (AS + SP) against P. falciparum were undertaken in sentinel sites in Afghanistan from 2007 to 2014, accompa-
nied by relevant molecular studies. The first study was a randomized trial of AS + SP versus dihydroartemisinin-pipe-
raquine, while two subsequent studies were standard therapeutic efficacy studies of AS + SP.
Results: Three hundred and three patients were enrolled across four provinces in the north and east of the coun-
try. Curative efficacy was high in all the trials, with an adequate clinical and parasitological response (ACPR) of more 
than 95 % in all groups and trial stages. Genotyping for drug-resistance alleles at dhfr indicated fixation of the S108 N 
mutation and a prevalence of the C59R mutation of approximately 95 % across all sites. Other mutations in dhfr and 
dhps remained rare or absent entirely, although five isolates from the first trial carried the dhps triple mutant SGEGA 
haplotype. In the last study undertaken in 2012–2014 the K13 artemisinin resistance marker was examined; only two 
of 60 successfully sequenced samples carried a K13-propeller mutation.
Conclusions: These data confirm maintained efficacy 10 years after introduction of artesunate plus SP as combina-
tion treatment of P. falciparum in Afghanistan. The molecular data indicate that despite a substantial fall in incidence, 
resistance has not developed to artemisinins, or intensified to the ACT partner drug components.
Trial Registration http://www.clinicaltrials.gov/ct NCT00682578, NCT01115439 and NCT01707199
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Background
Plasmodium falciparum transmission occurs at its most 
northerly latitudes in Afghanistan, where the distribu-
tion of cases is determined by the physical geography of 
the country, malaria being confined to lower lying areas 
with sufficient rainfall for mosquito survival. These con-
sist of the northern plains [1], the Jalalabad basin to the 
east (bordering Pakistan), and river valleys that fringe the 
central mountains to the west and south [2]. The central 
area of Afghanistan, occupied by the western end of the 
Hindu Kush mountain range, is relatively free of malaria 
[3, 4]. The incidence of clinical cases peaks in November 
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[5]. Following falls in incidence, northern areas are now 
preparing for malaria elimination in line with neighbour-
ing countries (Turkmenistan, Uzbekistan and Tajikistan).
Chloroquine-resistant P. falciparum was evident in 
Afghanistan and Pakistan by the 1990s [6–9] and the 
combination of artesunate with amodiaquine also proved 
to have low efficacy [7] consistent with spread of the 
SVMNT pfcrt haplotype [10]. However, sulfadoxine-
pyrimethamine (SP) retained reasonable efficacy in east-
ern [7] and northern Afghanistan (Kunduz province, 
2002–2003) [11], findings which suggested that AS + SP 
might be an efficacious therapy for falciparum malaria 
in the region. Combination therapy with AS  +  SP was 
adopted as recommended treatment for P. falciparum 
infection in a number of south Asian countries, becom-
ing first-line treatment in Afghanistan (2003), Iran 
(2006), Pakistan (2007) and India (2007).
This paper describes a series of therapeutic efficacy 
studies undertaken to examine the efficacy of AS +  SP 
against P. falciparum in sentinel sites in Afghanistan from 
2007 to 2014, accompanied by relevant molecular stud-
ies. These confirm maintained efficacy of the combina-
tion against P. falciparum with no evidence for increase 




Studies were undertaken at, or within 20  km of, four 
provincial control centres, two located to the north and 
two to the south and east of the Hindu Kush mountains. 
Jalalabad, capital of Nangarhar province, is a referral cen-
tre for the whole eastern region and lies adjacent to the 
Pakistani border where population movement in both 
directions takes place. The population is multi-ethnic 
with Pashtoon being the dominant group. The province 
as a whole is generally semiarid but where possible rice 
is cultivated. Asadabad is the capital city of Kunar prov-
ince, a largely mountainous area bordering Pakistan, with 
which there is uncontrolled movement via unofficial bor-
ders. Taloqan is the capital of the north-east province of 
Takhar with a population that is mainly Tajik with sig-
nificant proportions of Uzbek and Pashtoon. Rice is cul-
tivated on the plain and malaria is a well-known health 
problem [12]. Maimana is the capital city of the north-
west province of Faryab bordering Turkmenistan, with 
which there is no open border. The population is mainly 
Uzbek and Turkmen and the region is semi-arid.
Participants
Trial 1 was a prospective, open label, parallel group ran-
domized trial with a 1:1 allocation ratio of AS +  SP to 
dihydroartemisinin-piperaquine (DP) undertaken in 
all four centres. Trials 2 and 3 were therapeutic single-
arm efficacy studies of AS + SP undertaken in Jalalabad 
(Nangarhar province), and Asadabad (Kunar province) 
respectively. In all trials eligible participants were adults 
and children over 6 months old presenting with sympto-
matic, uncomplicated, microscopically confirmed mono-
infection with asexual stages of P. falciparum. Additional 
study inclusion criteria were the ability to swallow oral 
medication, ability and willingness to comply with the 
study protocol for the duration of the study and written 
informed consent (from a parent or guardian in the case 
of children under 18 years of age). In trial 1 there was no 
lower limit of asexual parasitaemia and patients with par-
asitemia of more than 100,000/µL were excluded. In trials 
2 and 3 only patients with 500–150,000/µL asexual forms 
were included.
In all trials exclusion criteria included the presence of 
general danger signs in children aged under 5  years or 
signs of severe falciparum malaria according to the defi-
nitions of WHO [13], mixed malaria infection, enroll-
ment in any other investigational study in the previous 
month, known underlying chronic disease requiring 
treatment, a history of hypersensitivity reactions or 
contraindications to any of the study medications and 
pregnancy. Pregnancy was excluded via urine dipstick 
testing, although unmarried females over 12 years of age 
were also included without a urine test given the cultural 
sensitivity of pregnancy testing in this group. In trial 1, 
treatment with antimalarials in the past month was an 
additional exclusion criterion. In trials 2 and 3, additional 
exclusion criteria were severe malnutrition (defined as 
a child whose growth standard is below −3 z-score, has 
symmetrical oedema involving at least the feet or a mid-
upper arm circumference < 110 mm), presence of febrile 
conditions due to diseases other than malaria and regu-
lar medication potentially interfering with antimalarial 
pharmacokinetics.
Trial methodology
Standard case record forms were used to record demo-
graphic information, details of symptoms and their dura-
tion, and previous antimalarial medications. Clinical 
examination findings and vital signs were documented, 
including axillary temperature measured with a digital 
thermometer. Blood samples were obtained for haemo-
globin measurement and Giemsa-staining of thick and 
thin blood films to confirm parasite species and parasi-
taemia by a standard approximation method (40 × num-
ber of parasites per 200 white blood cells on the thick 
film). Slide examination results were considered to be 
negative after examination of 200 oil fields of the thick 
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film. 20–100  µl baseline blood was collected on filter 
papers for subsequent confirmation of species by PCR 
and testing of drug resistance markers.
Interventions
For patients receiving AS + SP, each drug was dosed to 
the nearest half tablet, determined from a dosing chart 
[14] and broadly equivalent to a daily dose of 4 mg artesu-
nate/kg (once daily for 3 days) and a single dose of 25 mg 
sulphadoxine/kg on day 0. Trial 1 used 50  mg artesu-
nate tablets from Guilin Pharmaceutical, China and SP 
(500/25  mg tablets) from Roche, Switzerland. Trial 2 
used Guilin artesunate and SP (500/25 mg tablets) from 
Durbin Pharmaceuticals. Trial 3 used blister packs (Arte-
cospe® from Guilin Pharmaceutical Co. Ltd., China or 
Artesul from Zafa) containing SP tablets (500/25 mg) and 
50 or 100 mg artesunate tablets. In Trials 2 and 3, drugs 
were provided by WHO via the Afghanistan National 
Malaria Control Program after quality control in a pre-
qualified laboratory. Primaquine was not administered in 
any of the studies.
Patients receiving DP (trial 1 only) received Duo-
Cotecxin® (Holleypharm, China) in which each co-for-
mulated tablet contained 40 mg dihydroartemisinin and 
320  mg piperaquine phosphate. The target total dose of 
6/48 mg/kg was made up of three divided doses given on 
a daily basis. According to the body weight, individual 
doses were rounded to the nearest quarter tablet.
All doses of medicine were administered under the 
supervision of a qualified member of the staff designated 
by the principal investigator. The study patients were 
observed for 30  min after medicine administration for 
adverse reactions and/or vomiting. Patients who vom-
ited during this observation period were re-treated with 
the same dose of medicine and observed for an addi-
tional 30  min. Patients vomiting again were to be given 
parenteral (and subsequently oral) therapy with quinine 
sulphate (10 mg base per kg body weight three times per 
day), along with once daily tetracycline (clindamycin in 
children) according to national malaria treatment guide-
lines, and withdrawn from further study.
Follow‑up
Subjects were seen on days 0–3 inclusive and weekly to 
56 days (trial 1) or 42 days (trials 2 and 3). Patients were 
also requested to attend if they felt unwell on any other 
day during follow-up. At each follow up visit a clinical 
assessment was carried out and the patient was asked 
about adverse events by the use of a standard symptom 
questionnaire. Thick and thin blood slides were exam-
ined and haemoglobin was measured. Other tests such as 
peripheral white blood cell count and urine examination 
were undertaken as indicated to rule out other conditions 
and investigate possible adverse effects of drugs. Patients 
were censored from the analysis if there was stated with-
drawal of consent at any stage, persistent vomiting dur-
ing the acute phase (necessitating parenteral treatment) 
or occurrence during the follow-up of concomitant dis-
ease that would interfere with a clear classification of the 
treatment outcome (including infection with P. vivax). 
Patients failing to attend follow-up visits received a 
visit at home and were asked to re-attend the centre for 
scheduled assessments. Transportation was provided for 
all follow-up visits for all subjects. All enrolled patients 
were given one long-lasting insecticide-treated bed net.
Patients with recurrence of P. falciparum had capillary 
blood collected on filter paper for PCR analysis and were 
treated with oral quinine and tetracycline (clindamycin in 
children) for 7 days with standard follow up.
Outcomes
The primary outcome was the proportion of patients 
with PCR-corrected adequate clinical and parasitologi-
cal response (ACPR) at day 42 [15]. Secondary outcomes 
were the proportion of patients with PCR-corrected 
ACPR at day 28, crude or PCR-uncorrected ACPR, 
early treatment failure, parasite, fever and gametocyte 
clearance times, haemoglobin recovery and the rate and 
severity of adverse events.
Sample size
In trial 1 the aim was to examine whether DP was as 
effective as AS +  SP via a non-inferiority design, given 
the relatively high predicted efficacy of AS + SP [16]; the 
non-inferiority margin (Δ) was set at 5  %. Sample size 
was 550 patients (275 per arm), calculated assuming a 
95  % cure rate with AS +  SP, a one-sided alpha of 0.05 
and 80 % power.
Trials 2 and 3 were single arm monitoring studies and 
a sample size of 100 was chosen in each case consistent 
with WHO guidelines for therapeutic efficacy studies 
[15].
Randomisation and blinding (trial 1)
Patients were allocated to the two treatment arms based 
on a randomization list created using Stata 9.0 statisti-
cal software (StataCorp, College Station, TX) with a 1:1 
allocation using a block size of 20 that was produced and 
held independently of the field teams by a statistician. The 
individual treatment allocations were kept in sequentially 
numbered, opaque, sealed envelopes and opened by the 
relevant field worker only after participant enrolment by 
the field team. Patients and clinical field workers were not 
blinded to the treatment arm after allocation. Laboratory 
workers assessing blood films and genotyping were not 
informed of the treatment arm.
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Statistical methods
Data were entered into Microsoft Access or the WHO 
Study Information Sheet for calculation of baseline char-
acteristics. Subsequent analyses were conducted using 
STATA (versions 10–12, Statcorp, USA) and GraphPad 
Prism (GraphPad, USA). The Student’s t test, Mann–
Whitney U and Chi squared (or Fisher’s exact) tests were 
used for comparison of baseline variables between the 
two treatment arms of trial 1 and Wilson’s test was used 
for calculation of confidence intervals for ACPR.
Pharmacological studies
Day 7 blood samples were collected for drug measure-
ments in Nangarhar and Kunar provinces in year 3 of 
trial 1, during the period September to December 2009. 
Approximately 100 µl capillary blood was collected onto 
Whatman 3MM filter papers and stored individually 
with silica gel for transportation to the Department of 
Clinical Pharmacology at MORU. Piperaquine concen-
trations (DP arm), adjusted for estimated sample vol-
ume, were determined by liquid chromatography and 
tandem mass spectrometry as described previously 
[17, 18]. Sulphadoxine concentrations (AS  +  SP stud-
ies) were determined by high performance liquid chro-
matography coupling with ultraviolet detector. This 
method is based on the method developed by Green 
et  al. [19] with a slightly extended calibration range at 
both ends. Quality control samples (low, medium and 
high concentration) were analysed in triplicates within 
each batch to ensure accuracy and precision during 
routine drug measurements of clinical samples. Total 
accuracy and precision were below 7 % CV for all qual-
ity control samples. The lower limit of quantification 
was set to 3  ng/mL for piperaquine and 2  µg/mL for 
sulphadoxine.
Genotyping of baseline and recurrent infections
Blood samples were collected on filter paper (Whatman 
3MM) at enrollment and at any visit where parasites 
were observed after day 7. Each filter paper was dried 
and stored individually in a plastic bag containing silica 
gel. All filter papers were subsequently transported to the 
Faculty of Tropical Medicine, Mahidol University. Para-
site DNA from dried blood spots was extracted via the 
QIAmp DNA Mini kit using the standard protocol and 
stored at −20 °C until use. Nested PCR was performed to 
detect P. falciparum according to established methods. In 
order to differentiate a recrudescence from a reinfection, 
a genotype analysis was conducted based on the exten-
sive genetic diversity in the polymorphic genes msp1, 
msp2 and glurp. The genotypic profiles of pre- and post-
treatment strains were compared by standard methods 
[20].
PCR–RFLP and sequencing was undertaken for base-
line samples in trial 1 examining pfdhr, pfdhps, pfcrt 
and pfmdr1 single nucleotide polymorphisms (SNPs) 
and pfmdr1 copy number assessment using previously 
described techniques [21, 22]; these data have already 
been published [23]. In trials 2 and 3 SNPs in pfdhr and 
pfdhps alone were examined and in trial 3 the artemisinin 
resistance marker K13 propeller [24] was sequenced 
using established techniques [25]. Heterozygous samples 
with evidence of both wild-type and mutant sequence 
were counted as mutants in overall calculations.
Ethical approval
All trials were approved by the Oxford Tropical Research 
Ethics Committee, Oxford University, UK (Refs. 032-07, 
06-10 and 164-12) and the Institutional Review Board of 
the Afghanistan National Public Health Institute, Min-
istry of Public Health, Afghanistan. In addition trial 1 
was approved by the Ethics Committee of the Faculty of 
Tropical Medicine, Mahidol University, Thailand and tri-
als 2 and 3 were approved by the Ethical Review Commit-
tee of the WHO.
Results
Trial profile and progress
Trial 1 ran from October 2007 to February 2010. Across 
the four control centres, 120 cases were enrolled, receiv-
ing DP (n = 59) or AS + SP (N = 61); one patient in the 
DP arm withdrew after two doses of treatment (Fig.  1). 
Given the clear futility of achieving the planned sample 
size (550) within a reasonable timeframe, and the evi-
dent efficacy of first-line treatment (AS +  SP), the trial 
was stopped and activities shifted to single arm thera-
peutic efficacy studies aiming to recruit 100 patients 
each, in line with WHO guidelines [15]. Trial 2 ran from 
August 2010 to February 2011 in malaria treatment cen-
tres in and around Jalalabad. One hundred patients were 
enrolled and all completed 3  days of treatment. Trial 3 
ran from October 2012 to January 2014 in treatment cen-
tres in Pech, Shigal, Narang, Khuskunar and Khaskunar 
districts of Kunar province. 83 patients were recruited 
over two P. falciparum transmission seasons, with three 
withdrawing before completion of treatment. Given evi-
dence of falling transmission, it was decided not to con-
tinue recruitment into a third season. Overall follow-up 
rates to day 42 were more than 90 % (Fig. 1).
Baseline characteristics
In trial 1 baseline characteristics were similar between 
the two treatment groups except for a higher propor-
tion of patients with gametocytes in the AS  +  SP arm 
(p = 0.003) (Table 1). Baseline parasitaemia was compa-
rable across all trials.
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Outcomes
Therapeutic efficacy was high in all the trials, with an ACPR 
of more than 95 % in all groups and trial stages (Table 2). 
There were no recrudescences in trials 1 or 3 and only 2 in 
trial 2, indicating an overall day 42 efficacy of 97.8 % (92.4–
99.4). In trial 2 a partial sensitivity analysis (assuming two 
undefined recurrences to be recrudescences) indicated an 
ACPR rate of 95.7 % (89.6–98.3 %). No patient deteriorated 
or developed signs of severity and there were no early treat-
ment failures. There were no serious adverse events and no 
cases of repeated vomiting of the study medication.
Secondary analyses
Parasite clearance was rapid in all trials. Across the three 
trials, asexual parasites were found at day 1 after treat-
ment in only 18 of 300 patients (6 %) and at day 2 in 3 of 
297 patients (1 %) with no patients remaining positive at 
day 3. In the randomized trial of DP vs. AS + SP, there 
were no differences between the groups in terms of the 
proportion of patients with gametocytes or fever (tem-
perature more than 37  °C) after treatment (Fig.  2a, b). 
Haemoglobin recovery was also similar between the two 
arms of trial 1 (Fig. 2c).
P. falciparum positive cases 
assessed for eligibility (n=140) 
120 cases randomised 
Excluded (n=20) 
   Refusal of consent (n=3) 
   Anticipated difficulty with follow-up (n=3) 
   Concomitant disease (n=4) 
   Pregnancy or lactation (n=8) 
   Signs of severity (n=2) 
Allocated to AS+SP (n=61) 
   Received all AS+SP doses (n=61) 
Lost to follow-up by d28 (n=4)* 
Further loss to follow-up by d42 (n=1) 
Further loss to follow-up by d56 (n=4) 
Completed to d28 without failure (n=57) 
Completed to d42 without failure (n=56) 
Completed to d56 without failure (n=52) 
Allocated to DP (n=59) 
   Received all DP doses (n=58) 
   Did not complete DP (n=1) 
Lost to follow-up by d28 (n=5) 
Further loss to follow-up by d42 (n=1) 
Further loss to follow-up by d56 (n=2) 
Completed to d28 without failure (n=53) 
Completed to d42 without failure (n=52) 
Completed to d56 without failure (n=50) 
TRIAL 1 (Four centres, 2007-2010) 
Recurrence by d56 (n=0) Recurrence by d56 (n=0) 
P. falciparum positive cases 
assessed for eligibility (n=127) 
100 cases recruited 
Excluded (n=27) 
   Refusal of consent (n=10) 
   Anticipated difficulty with follow-up (n=7) 
   Concomitant disease (n=4) 
   Pregnancy or lactation (n=3) 
   Mixed infection (n=2) 
   Signs of severity (n=1) 
Allocated to AS+SP (n=100) 
Received all AS+SP doses (n=100) 
Lost to follow-up by d28 (n=3) 
Further loss to follow-up by d42 (n=0) 
Recurrence by d28 (n=1) 
Further recurrence by d42 (n=6) 
TRIAL 2 (Nangarhar Province, 2010-2011) 
Completed to d28 without failure (n=96) 
Completed to d42 without failure (n=90) 
P. falciparum positive cases 
assessed for eligibility (n=124) 
83 cases recruited 
Excluded (n=41) 
   Refusal of consent (n=10) 
   Anticipated difficulty with follow-up (n=9) 
   Concomitant disease (n=7) 
   Pregnancy, lactation (n=13) 
   Mixed infection (n=2) 
Allocated to AS+SP (n=83) 
Received all AS+SP doses (n=80) 
Lost to follow-up by d28 (n=2) 
Further loss to follow-up by d42 (n=1) 
Recurrence by d28 (n=0) 
Further recurrence by d42 (n=1) 
TRIAL 3 (Kunar Province, 2012-2014) 
Completed to d28 without failure (n=78) 
Completed to d42 without failure (n=76) 
Fig. 1 Trial flow. *In trial 1 the four cases lost to follow-up at d28 include one P. vivax infection at d28
Table 1 Baseline characteristics
Parameter Study
Trial 1 Trial 2 Trial 3
DP AS + SP AS + SP AS + SP
Year 2007–2010 2007–2010 2010–2011 2012–2014
No. of patients 59 61 100 83
Location (%)
 Jalalabad 41 (69) 42 (69) 100 (100) –
 Takhar 6 (10) 5 (8) – –
 Faryab 1 (2) 3 (5) – –
 Kunar 11 (19) 11 (18) – 83 (100)
Age (years) (median, range) 11 (2–52) 13 (1–70) 15.5 (3–55) 18 (1–74)
Gender male/female (ratio) 43/16 (2.7) 35/26 (1.3) 60/40 (1.5) 49/34 (1.4)
Body weight (kg) (median, range) 31 (8–87) 35 (7.5-85) 50 (10-72) 49 (10–75)
Median parasitaemia/µl (range) 6760 (1220–90,000) 7200 (900–62,160) 4680 (1000–95,000) 3220 (500–59,520)
No. of patients with gametocytes (%) 13 (22) 29 (48) 19 (19) 42 (51)
Mean axillary temp (°C) ± SD 37.9 ± 1.1 37.9 ± 1.0 38.4 ± 0.8 38.4 ± 0.9
Mean hemoglobin (g/dl) ± SD 11.2 ± 1.3 11.2 ± 1.4 11.50 ± 0.9 11.6 ± 1.9
Mean total drug dose (mg/kg) ± SD
 Artemisinin derivative 6.7 ± 1.2 (DHA) 10.42 ± 1.9 (AS) 10.5 ± 2.0 (AS) 10.5 ± 2.4 (AS)
 Partner drug 53.9 ± 9.3 (PIP) 27.35 ± 11.9 (SUL) 26.8 ± 5.0 (SUL) 27.3 ± 6.1 (SUL)
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Mean ± SD day 7 drug levels (adjusted for sample vol-
ume) for piperaquine were 98.5  ±  73.3  ng/mL (n  =  20 
patients), although in two cases levels were less than the 
limit of detection (0.75  ng/mL). There was a non-signifi-
cant positive correlation between piperaquine concentra-
tion and the body weight-normalized total dose (Spearman 
r = 0.43, p = 0.06). Day 7 sulphadoxine levels were below 
the limit of detection (0.5 µg/mL) in nine of the 17 patients 
studied (spanning a range of ages), a finding that is chal-
lenging to correlate with the high measured efficacy.
Molecular data
Genotyping for drug-resistance alleles at dhfr indicated 
fixation of the S108 N mutation and that approximately 
95 % of parasites carried the C59R mutation (combining 
all three studies, Fig. 3, Table 3). There were no cases of 
mutation at dhfr A16, N51 or I164 and most parasites 
were wild-type across the dhps gene, with 0.5, 7.7, 2.6 and 
10.1  % of isolates carrying mutations at positions 436, 
437, 540 and 581 respectively (Table 3). These tended to 
be combined within haplotypes, with the K540E muta-
tion only found as part of a SGEGA haplotype in trial 1 
in one and four isolates from Nangarhar and Kunar prov-
inces respectively. K540E was not seen again in the fol-
low-up trials from either location.
In trial 3, 58 out of 60 samples successfully sequenced 
at the K13-propeller locus were wild-type; the other sam-
ples had a Y493C and a S700L mutation. The patients 
carrying these isolates had negative blood smears on day 
1 (24 h after the start of treatment).
Discussion
Prospective trials of the clinical efficacy of AS  +  SP, 
spanning the decade following its introduction as first-
line recommended treatment for P. falciparum infec-
tion in Afghanistan, provide very reassuring evidence of 
maintained efficacy with rates of ACPR well over 95 % 
in all studies. Accompanying assessments of molecu-
lar markers explain these clinical responses. As in 
the rest of Asia and much of sub-Saharan Africa, two 
polymorphisms in dhfr (59R and 108  N) remain at or 
near fixation, but no other dhfr mutations are found 
in Afghanistan. A previous report generated con-
cerns over the prevalence of the dhps triple mutation 
437G/540E/581G in Nangarhar and Kunar provinces 
(the molecular data for trial 1 of this paper) [23] but 
the subsequent data indicate no evidence of this triple 
mutation in either province, and there was no increase 
in the individual mutations that make up the haplo-
type. In summary, there is no phenotypic or genotypic 
Table 2 Efficacy at day 28, day 42 and day 56 (trial 1 only) expressed as percentage with ACPR
Successful follow-up indicates patients seen up to and including the corresponding time point. Recurrences due to reinfection and one patient in the AS + SP arm 
with P. vivax infection at d28 were censored from analysis
DP AS + SP T1 AS + SP T2 AS + SP T3
N (enrolled) 59 61 100 83
d28
 Successful follow-up 53 57 97 78
 Reinfection 0 0 0 0
 Analysed 53 57 97 78
 Recrudescence 0 0 1 0
 ACPR % (95 % CI) 100 (93.2–100) 100 (93.7–100) 99.0 (94.4–99.8) 100 (95.3–100)
d42
 Successful follow-up 52 56 97 77
 Recurrence: reinfection 0 0 3 1
 Recurrence: unknown genotype 0 0 2 0
 Analysed 52 56 92 76
 Recrudescence 0 0 2 0
 ACPR (95 % CI) 100 (93.1–100) 100 (93.6–100) 97.8 (92.4–99.4) 100 (95.2–100)
d56
 Successful follow-up 50 52
 Recurrence: reinfection 0 0
 Recurrence: unknown genotype 0 0
 Analysed 50 52
 Recrudescence 0 0
 ACPR (95 % CI) 100 (92.9–100) 100 (93.1–100)
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evidence of worsening resistance to SP a decade after 
the introduction of AS + SP in Afghanistan.
Compared to this, neighbouring countries show rela-
tively more concerning resistance marker profiles. 
Surveys from Pakistan within the last decade show sig-
nificant numbers of parasites mutated at DHPS 437G 
[26–28] as well as 540E and 581G (generally in mixed 
infections) [28]. Studies in central India [29, 30] and 
Iran [31, 32] also describe increasing mutations at 437G. 
However, AS + SP treatment of P. falciparum does not 
yet appear to have been significantly compromised 
by molecular changes in any of these locations. Only 
in northeast India is there evidence for a high preva-
lence of ‘quintuple’ mutation haplotypes based on these 































































Fig. 2 Secondary outcomes in trial 1. Fever (a) and gametocyte (b) clearance and haemoglobin recovery (c) in the two arms of trial 1 (AS + SP vs. 
DHA-piperaquine)
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two genes [33] in association with reports of failure of 
AS + SP.
This is the first study to examine the K13 artemisinin 
resistance marker in Central Asia. Only two samples (less 
than 5 %) contained a mutation in the propeller domain; 
Y493C and S700L. Neither mutation has been previously 
reported, although a different mutation at 493, Y493H, 
is common and causally linked to artemisinin resistance 













































































































































Fig. 3 Molecular data. The proportion of wild-type and mutant isolates is shown for five loci in each of dhfr and dhps (all trials) and the K13 propel-
ler region (trial 3 only). a–c refer to the three separate trials undertaken, as indicated above each graph
Table 3 Molecular findings
Number of wild-type/mutant samples at five resistance loci in each of the dhfr and dhps genes, and resulting haplotypes (with mutations in italics). Results indicating 
mixed wild-type/mutant alleles were counted as mutations. Only haplotypes in which all five loci were successfully determined are described
a One sample had the dhps A437S mutation
Study Trial 1 Trial 2 Trial 3 Total
Province Jalalabad Takhar Faryab Kunar Jalalabad Kunar
DHFR % with mutation
 A16 V 32/0 3/0 2/0 7/0 71/0 49/0 164/0 0
 N51I 32/0 3/0 2/0 7/0 71/0 49/0 164/0 0
 C59R 2/30 0/3 0/2 0/7 5/66 2/47 9/155 94.5
 S108 N 0/32 0/3 0/2 0/7 0/71 0/49 0/164 100.0
 I164L 32/0 3/0 2/0 7/0 70/0 49/0 163/0 0
DHPS
 S436A 43/0 6/0 2/0 9/0 83/0 53/1 196/1 0.5
 A437G 38/3 6/0 1/1a 4/4 80/3 50/4 179/15 7.7
 K540E 42/1 6/0 2/0 5/4 83/0 52/0 190/5 2.6
 A581G 40/3 6/0 1/1 5/4 34/0 47/7 133/15 10.1
 A613S 43/0 6/0 2/0 9/0 34/0 54/0 148/0 0
DHFR haplotype Proportion (%)
 ANCNI 2 5 2 9 5.5
 ANRNI 30 3 2 7 65 47 154 94.5
DHPS haplotype
 SAKAA 38 6 1 4 34 41 124 86.7
 SAKGA 6 6 4.2
 SGEGA 1 4 5 3.5
 SGKAA 1 3 4 2.8
 SGKGA 1 1 2 1.4
 SSKGA 1 1 0.7
 AAKAA 1 1 0.7
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in Cambodia [24, 34]. The patients carrying these iso-
lates had rapid parasite clearance. Overall, the data indi-
cate that isolates remain fully sensitive to artemisinins in 
Afghanistan.
The maintained efficacy of AS + SP, with no evidence 
of adaptive evolution in the dhps gene or increasing 
mutations in dhfr, is to some degree reminiscent of the 
return of in  vitro mefloquine sensitivity following addi-
tion of artesunate to mefloquine at the Thai–Myanmar 
border in the 1990s [35]. While use of anti-malarials as 
ACT is predicted to protect against worsening resist-
ance [36], it is not clear why AS + SP has retained its effi-
cacy in Afghanistan over the course of 10  years despite 
a degree of pyrimethamine resistance at the outset, the 
lack of an available coformulation and clear evidence of 
worsening sensitivity in neighbouring countries. Factors 
that may have contributed to the maintained efficacy 
include restriction in terms of access to anti-malarials, a 
lack of fake or substandard anti-malarials and human fac-
tors, such as a tendency to complete prescribed courses.
Conclusions
AS +  SP, the first-line treatment for falciparum malaria 
in Afghanistan, remains efficacious therapy for uncom-
plicated falciparum malaria, both in terms of initial 
parasite clearance and cure. Accompanying molecular 
data indicate a stable situation with regard to SP resist-
ance, and suggest that AS + SP is likely to retain a high 
level of efficacy as treatment for P. falciparum for a sub-
stantial period of time as Afghanistan moves towards 
elimination.
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